Pascal Biosciences Inc (CVE:PAS)’s share price hit a new 52-week low during trading on Monday . The company traded as low as C$0.20 and last traded at C$0.21, with a volume of 40000 shares. The stock had previously closed at C$0.22.
The firm has a market capitalization of $11.32 million and a P/E ratio of -2.87.
About Pascal Biosciences (CVE:PAS)
Pascal Biosciences Inc, a drug discovery and development company, researches and develops biotechnology products for the treatment of cancer and for the enhancement of immune system in Canada. Its research programs include the development of Anti-VpreB, a therapeutic monoclonal antibody for treatment of B-cell precursor acute lymphoblastic leukemia in collaboration with the University of New Mexico; optimization of novel classes of molecules that restore immune recognition and killing of cancer cells; and regulating activity of immune system calcium channels to combat cancers, infections, and autoimmune diseases.
Featured Story: Municipal Bonds
Receive News & Ratings for Pascal Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pascal Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.